Outlook Therapeutics' Series A Round

Outlook Therapeutics raised a round of funding on July 27, 2015.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal an…

Articles about Outlook Therapeutics' Series A Round: